Литература по теме: «Эффективность сертиндола у больных шизофренией с преобладанием негативной симптоматики»


  1. Аведисова А. С., Чахава К. О., Ястребов В. В. Эффективность и переносимость препарата сердолект при неврозоподобной шизофрении с преобладанием в клинической картине заболевания симптомов астении//Ж. Социальная и клиническая психиатрия, 2010, том. 20, N.2, с. 39-44.
  2. Вовин Р.Я., Иванов М. В. Опыт применения флюанксола в терапии негативного симптомокомплекса и депрессивных нарушений при эндогенных психозах//Ж. Социальная и клин, психиатрия, 1999,4, с. 68-72.
  3. Горобец Л.Н., Матросова М. И., Шмуклер А. Б., Динамика клинико-эндокринных, гормональных, биохимических, антропометрических и физикальных показателей у больных шизофренией и расстройствами шизофренического спектра в процессе терапии сертиндолом//Ж. Социальная и клиническая психиатрия, т. 20, N. 3, 2010, с. 59-67.
  4. Гурович И. Я., Шмуклер А. Б., Магомедова М. В. Соотношение нейрокогнитивного дефицита и социального функционирования у больных шизофренией и шизоаффективным расстройством на различных этапах заболевания//Журн. Социальная и клин, психиатрия, 2001,4, с. 31-35.
  5. Магомедова М. В. О нейрокогнитивном дефиците и его связи с уровнем социальной компетентности у больных шизофренией//Социальная и клинич. психиатрия, 2000, № 1, с. 92-98.
  6. Мосолов С. Н. Шкалы психометрической оценки симптомов шизофрении и концепция позитивных и негативных расстройств. М: Новый цвет, 2001, 238с.
  7. Мосолов С. Н., Кабанов С. О., Каримулаев И. О., Рыбкин П. В. Редукция когнитивных нарушений у больных с первым эпизодом шизофрении и хроническим течением болезни при лечении кветиапином//Журн. Психиатрия и психофармакотерапия, 2005: т. 7, № 1.
  8. Смулевич А. Б., Воробьёва В. Ю. Психопатология шизофренического дефекта (к построению интегративной модели негативных изменепий)//Ж. невропатологии и психиатрии им. С. С. Корсакова, 1986, т. 86, № 9, с. 100-105.
  9. Addington, D., Addington, J., Maticka-Tyndale, E. Assessing depression in schizophrenia: the Calgary Depression Scale//Brit. J. Psychiatry, 1993, Vol. 163 (suppl. 22), p. 39-44.
  10. Andreasen N. C., Olsen S. A., Dennert J.W. et al. New version Scale for the assessment of Negative symptoms//Psychiatry Psychobiol., 1986, № 2, p. 108-121.
  11. Andreasen N. C., Carpenter W.T. Jr., Kane J. M. et al. Remission in schizophrenia: proposed criteria and rational for consensus//Am.J. Psychiat., 2005, Vol. 162, p. 441-449.
  12. Azorin J. M., Strub N., Loft H. A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia//Int. Clin. Psychopharmacol., 2006, Vol. 21. № l,p. 49-56.
  13. Bilder R. M., Bates J. Neuropsychologicl prediction of neuroleptic treatment response// Prediction of neuroleptic treatment outcome in schizophrenia-concepts and methods. Gaebel W., Awad A.G. 9eds.).-New York: Springer-Verlag, 1994, p. 99-110.
  14. Branford D., Thompson B., Muldoon C. Mortality in three comparative cohorts of patients who received sertindole, risperidone, and olanzapine: a hospital-based retrospective study//Poster presented at ICPE. Edinburgh, 18-21 August 2002.
  15. Boyer P, Lecrubier Y., Peuch A. et al. Treatment negative symptoms in schizophrenia with amisulpride//Br.J. Psychiatry, 1995, Vol. 166, p. 68-72.
  16. Carpenter W.T. Heinrichs D.W., Wagman A.M.I. Deficit and nondeficit forms of schizophrenia: The concept//Am. J. Psychiatry 1988, Vol. 145, p. 578-583.
  17. Crow T. J. Positive and negative schizophrenic symptoms and the role of dopamine: Discussion 2//Br.J. Psychiatry, 1980, Vol. 137, p. 383-386.
  18. Chouinard G., Jones B., Remington G. et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients//J. Clin. Psychopharmacol 1993, Vol. 13, p. 25-40.
  19. Daniel D.G., Wozniak P., Mack R.J., McCarthy B.G. Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia//The Sertindole Study Group//Psychopharmacol. Bull., 1998, Vol. 34, p. 61-69.
  20. Danion J., Rein W., Fleurot O. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride//Am.J. Psychiatry, 1999, Vol. 156, p. 610-616.
  21. Davis J. M., Chen N., Glick I. D. A meta-analysis of the efficacy of second-generation antipsychotics//Arch. Gen. Psychiatry, 2003, Vol. 60, № 6, p. 553-564.
  22. Dossenbach M., O’Halloran R. A., Boland J. Change in clinical status and side effects of patients treated with either olanzapine or risperidone: 6 month results from the 3-year intercontinental schizophrenia outpatient health outcomes (IC-SOHO) observational study//International Congress on Schizophrenia Research, March 29-April 2,2003, Colorado Springs, CO.
  23. Fenton W. S., McGlashan T. H. Natural history of schizophrenia subtypes: II. Positive and negative symptoms and long-term course//Arch. Gen. Psychiatry, 1991, Vol. 48, p. 978-986.
  24. Gallhofer В., Jaanson P, Mittoux A. et al. Course of recovery of cognitive impairment in patients with schizophrenia: a randomized double-blind study comparing sertindole and haloperidol// Pharmacopsychiatry, 2007, Vol. 40, p. 275-288.
  25. Goldberg T. E., Goldman R. S., Burdick К. E., Malhorta A. K., Lencz T. et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?//Arch. Gen. Psychiatry, 2007, Vol. 64, p. 1115-1122.
  26. Gomez JC, Sacristan JA, Carrasco PR. Safety and effectiveness of olanzapine vs. other antipsychotic drugs in the treatment of outpatients with schizophrenia//Eur. Neuropsychopharmacol, 1999,9 (suppl. 5), S290.
  27. Green M.F., Kern R. S., Heaton R. K. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS//Schizophr. Res. 2004. Vol. 72, № 1. P. 41-51.
  28. Green M. F. What are functional consequences of neurocognitive deficit in schizophrenia?// Am.J. Psychiatry., 1996, Vol. 153, p. 321-330.
  29. Green M.F., Kern R. S., Braff D., MintzJ. Neurocognition and functional outcome in schizophrenia: are we measuring the right stuff?//Schizophr. Bull., 2000, Vol. 26, p.119-136.
  30. Hale A. S. A review of the safety and tolerability of sertindole//Int. Clin. Psychopharmacol., 1998, Vol. 13, Suppl. 3, p. S65-S70.
  31. Hale A. S., Azorin J.-M., Kasper S. et al. Sertindole improves both the positive and negative symptoms of schizophrenia: results of a phase III trial//Int.J. Psych. Clin. Pract., 2000a, Vol. 4, p. 55-62.
  32. Hale A. S., Azorin J.-M., Kasper S. et al. Sertindole is associated with a low level of extrapyramidal symptoms in schizophrenic patients: results of base III trial//Int. J. Psych. Clin. Pract., 2000b, Vol. 4, p. 47-54.
  33. Harvey P. D., Koren D., Reichenberg A., Bowie C. R. Negative symptoms and cognitive deficits: What is the nature of their relationship?//Schizophr. Bull., 2006, Vol. 32, p. 250-258.
  34. Ho B., Miller D., Nopoulos P. et al. A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia//J. Clin. Psychiatry, 1999,60, p. 658-663.
  35. Hyttel J., Nielsen J. B., Nowak G. The acute effect of sertindole on brain 5-HT2, D2 and alpha 1 receptors (ex vivo radioreceptor binding studies)//J. Neural. Transm. Gen., 1992, Vol. 89, p. 61-69.
  36. Kane J. M. Sertindole a review of clinical efficacy//Int. Clin. Psychopharmacol., 1997, Vol. 13, Suppl. 3, p. S9.
  37. Kasper S., Toumi M. The clinical safety and tolerabiliry profile of sertindole// Int.J. Neuropsychopharmacol., 2004, Vol. 7, Suppl. I, p. S422.
  38. Kay S.R., Fizbein A., Opler L. A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia//Schizophr. Bull., 1987, Vol. 13, № 2, p. 261-276.
  39. Kraepelin E. Dementia praecox and paraphrenia – Livingstone, Edinburg, 1919.
  40. Lecrubier Y., Quintin P., Bouhassira M., Perrin E., Lancrenon S. The treatment of negative symptoms and deficit states of chronic schizophrenia: Olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial//Acta Psychiatrica Scand., 2006, Vol. 114, №5, p. 319-327.
  41. Leucht S., Komossa K., Rummel-Kluge C., et al. A meta-analysis of head to head comparisons of second generation antipsychotics in the treatment of schizophrenia//Am.J. Psychiatry, 2009; 166, p. 152-163.
  42. Leucht S., Corves C., Arbter D., Engel R. R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis//Lancet, 2009, V. 373,9657, p. 31-41.
  43. Lewis R., Bagnall A. M., Leitner M. Sertindole for schizophrenia//Cochrane Database Syst. Rev., 2005, Vol. 20, № 3, CD001715.
  44. Lieberman J. A., Stroup T.S., McEvoyJ.P. et al. Effectiveness of Antipsychotic Drugs in Chronic Schizopfrenia//The New England Journal of Medicine. 2005. Vol. 353. № 12. P. 1209-1223.
  45. Liddle P. F. The symptoms of chronic schizophrenia. A re-examination of the positive-negative dichotomy//Br. J. Psychiatry 1987a, Vol. 151, p. 145-151.
  46. Liddle P. F. Schizophrenic syndromes, cognitive performance and neurological dysfunction// Psychol. Med, 1987b, Vol. 17, p.49-58.
  47. Lindenmayer J. P., Grochovski S., Hyman R. B. Five factor model of schizophrenia: Replication across samples//Schizophr. Res., 1995, Vol. 14, p. 229-234.
  48. Lindenmayer J.P., Kay S. R., Friedman C. Negative and positive schizophrenic syndromes after the acute phase: A prospective follow-up//Comp. Psychiatry 1986, Vol. 27, p. 276-286.
  49. Lis S., Krieger S., Gallhofer B. et al. Sertindole is superior to haloperidol in cognitive performance in patients with schizophrenia, a comparative study II//Eur. Neuropsychopharmacol., 2003, Vol. 13, Suppl. 4, p. S323.
  50. Loo H., Poirier-Littre M., Theron M. et al. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia//Br.J. Psychiatry, 1997, Vol. 170, p. 18-22.
  51. Lublin H., Eberhard J., Levander S. Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics//Int. Clin. Psychopharmacol., 2005, Vol. 20, S. 4, p. 183-198.
  52. Milev P, Но В. C., Arndt S., Andreasen N. C. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: A longitudinal first-episode study with 7-year follow-up//Am.J. Psychiatry, 2005, Vol. 162, p. 495-506.
  53. Mӧller H.J. Treatment of negative symptoms. APA 159th Annual Meeting Industry-Supported Symposium 33, 2006; 65-80.
  54. Mӧller H.J. Management of the negative symptoms of schizophrenia: New treatment options//CNS Drugs, 2003, Vol. 17, p. 793-823.
  55. Mӧller H. J., Muller H., Borison R. L., Schooler N. R., Chouinard G. A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients//Eur Arch Psychiatry Clin Neurosc., 1995, Vol. 245, p. 45-49.
  56. Mӧller H.J., Van Praag H., Aufdembrinke B. et al. Negative symptoms in schizophrenia: considerations for clinical trials//Psychopharmacol., 1994, Vol. 115, p. 221-228.
  57. Mortimer A.M. Cognitive function in schizophrenia: do neuroleptics make a difference?// Pharmacol. Biochm. Behav., 1996, Vol. 56, p. 789-795.
  58. Morosini P. L., Magliano L., Brambilla L., Ugolini S., Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning//Acta Psychiatrica Scandinavica, 2000, Vol. 101, p. 323-329.
  59. Naber D., Lambert M. Sertindole decreases hospitalization and improves the quality of life of schizophrenic patients//Int.J. Psychiatry Clin. Pract., 1998, Vol. 2, Suppl. 2, p. S73 – S77.
  60. Olie J. P, Spina E., Murray S., Yang R. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: Results of a 12-week, double-blind study//Int. Clin. Psychopharmacol., 2006, Vol. 21(3), p. 143-151.
  61. Perquin L., Steinert T. A review of the efficacy, tolerabiliry and safety of sertindole in clinical trials//CNS Drugs, 2004, Vol. 18, Suppl. 2, p. 19-30.
  62. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: A multinational, multi-center, double-blind, parallel-group study versus haloperidol//Br.J. Psychiatry 1995, Vol. 166, p. 712-26.
  63. Peuskens J., Bech P, Moller H.J., Bale R., Fleurot O., Rein W. Amisulpride vs risperidone in the treatment of acute exacerbations of schizophrenia//Psychiatry Res., 1999, Vol. 88, № 2, p. 107-117.
  64. Potkin S. G. Taking control of negative symptoms: The next step for improved patient outcomes in schizophrenia//APA 159th Annual Meeting Industry-Supported Symposium 33, Guidebook, 2006, p. 17-22.
  65. Phillips M. L., David A. S. Cognitive impairments as causes of positive symptoms in schizophrenia//Cognition in schizophrenia. Impairments, importance, and treatment strategies// University Press, Oxford, New York, 2000, p. 210-228.
  66. Rodrigez-Gimenez R., Martiner I., Jimener-Arriero M. A. et al. Correlation between cognitive functions and the PANSS cognitive factor in schizophrenic patients//Congress Biol.Psychiatry, Poster, 2007.
  67. Stahl S. M., Buckley P E Negative symptoms of schizophrenia: a problem that will not go away//Acta Psychiatr Scand., 2007, Vol. 115, p. 4-11.
  68. Storosum J., Elferink A., Van Zwieten B., Van Strik R., Hoogendijk W., Broekmans A. Amisulpride: Is there a treatment for negative symptoms in schizophrenia patients?// Schizophr. Bull., 2002, Vol. 28, № 2, p. 193-201.
  69. Strip E., Lussier I., Babai M., et al. Seroquel and cognitive improvement in patients with schizophrenia//Biol. Psychiatry 1996, Vol. 40, p. 434-435.
  70. Sharma T., Mockler D. The cognitive efficacy of atypical antipsychotics in schizophrenia//J. Clin Psychopharmacol., 1998, Vol. 18, p. 12-19.
  71. Sharma T, Harvey Ph. Cognition in schizophrenia. Impairments, importance, and treatment strategies.- University Press, Oxford, 2000,363p.
  72. Simpson G. M., Angus I.W. S. A rating scale for extrapiramide side effects//Acta Psychiat Scand 1970, Vol. 46, 212, p. 11-18.
  73. Tamminga C. A., Mack R. J., Granneman G. R. et al. Sertindole in the treatment of psychosis in schizophrenia efficacy and satety//Int. Clin. Psychopharmacol., 1997, Vol. 12, Suppl. 1, S29-S35.
  74. Tandon R., Ribeiro S. С. M., DeQuardo J. R. et al. Covariance of positive and negative symptoms during neuroleptic treatment in schizophrenia: a replication//Biol. Psychiatry, 1993, Vol. 154, p. 466-474.
  75. Тек C., Kirkpatrick B., Buchanan R. W. A five-year follow-up study of deficit and nondeficit schizophrenia//Schizophr. Res., 2001, Vol. 49, p. 253-260.
  76. van Kammen D. P, McEvoy J. P, Targum S.D. et al. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia//Psychopharmacol., 1996, Vol. 124, p. 168-175.
  77. Velligan D. I., Miller A. L. Cognitive disfunction in schizophrenia//J. Clin. Psychiatry, 1999, Vol. 60, S. 25-28.
  78. Weiser M., Shneider-Beeri M., Nakash N., Brill N., Bawnik O., Reiss S. et al. Improvement in cognition associated with novel antipsychotic drugs: a direct drug effect or reduction of EPS?// Schizophr. Res., 2000, Vol. 46, p. 81-89.
  79. Weiss E., Bilder R., Fleischhacker W. The effects of second-generation antipsychotics on cognitive functioning and psychosocial outcome in schizophrenia//Psychopharmacology, 2002, Vol. 162, p. 11-17.
  80. Wehnert A., Mack R., Stilwell C., Rasmussen C., Silber C. Direct effect of sertindole on the primary negative symptoms of schizophrenia//6th World congress of Biological Psychiatry, Poster, 1997.
  81. Zimbroff D. L., Kane J. M., Tamminga C. A. el al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia//Am. J.. Psychiatry, 1997, Vol. 154, p. 782-791.

Если вы нашли ошибку, пожалуйста, выделите фрагмент текста и нажмите Ctrl+Enter.